Severe pulmonary toxicity in a patient treated with gemcitabine

Am J Clin Oncol. 2002 Feb;25(1):31-3. doi: 10.1097/00000421-200202000-00005.

Abstract

Gemcitabine is a pyrimidine analog of deoxycytidine with activity against nonhematologic and hematologic malignancies. Its pulmonary toxicity is usually mild and self-limiting. We describe a male patient with lung cancer in whom severe dyspnea and interstitial infiltrates developed after the administration of gemcitabine.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / secondary
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / adverse effects*
  • Deoxycytidine / adverse effects*
  • Deoxycytidine / analogs & derivatives*
  • Dyspnea / chemically induced
  • Gemcitabine
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Male

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Gemcitabine